Preclinical studies from our group combining XPO1 inhibitor (selinexor) and menin inhibitor (ziftomenib) inhibited MLL-r and NPM1-m AML cells in vitro and in vivo [81]. This evidence concerns the gene KMT2A and acute myeloid leukemia.